X

Drug Profile

Cancer gene therapy - Cell Genesys/EntreMed

Alternative Names: Angiogenesis inhibitor gene therapy - Cell Genesys/EntreMed; Angiostatin/endostatin gene therapy - Cell Genesys/EntreMed

Latest Information Update: 13 Aug 2003

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cell Genesys; EntreMed
Class Antineoplastics; Gene therapies
Mechanism of Action Angiogenesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer

Most Recent Events

25 Nov 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
21 Jun 2002 Preliminary preclinical study results have been added to the pharmacodynamics section
05 Mar 2001 Profile reviewed but no significant changes made

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com